|
Many of the most dynamic CEO's in the region have spoken at previous symposiums. Past keynote speakers who have shared their perspectives on the industry's successes and challenges have included:
- Michel de Rosen, president & CEO, ViroPharma, Inc.
- Boomer Esiason, co-chair, The Boomer Esiason Foundation
- Irwin Lerner, chairman & director, Medarex, Inc.
- G. Kelly Martin, president and chief executive officer, Elan Corporation, plc
- Margaret G. McGlynn, R.Ph., president, vaccines and infectious disease, Merck & Co., Inc.
- Stelios Papadopoulos, Ph.D., vice chairman, SG Cowen
- Joseph Scodari, chairman, worldwide pharmaceuticals, Johnson & Johnson
- Harlan F. Weisman, M.D., chief science and technology officer, medical devices & diagnostics, Johnson & Johnson
Speakers from Biotech 2007 include:
- Al Altomari, COO, Barrier Therapeutics
- David Anderson, CEO, Gentis, Inc.
- Gwilym Attwell, principal, Fish & Richardson P.C.
- Fredric Bader, Ph.D., vice president, new technology and business management, Johnson & Johnson/Centocor, Inc.
- Valli Baldassano, attorney at law, Fox Rothschild LLP
- Louis Beardell, Jr., partner, Morgan, Lewis & Bockius LLP
- Michael Becker, president & CEO, Cytogen
- Melvin Billingsley, Ph.D., president & CEO, Life Sciences Greenhouse of Central Pennsylvania
- Gilbert Block, M.D., Ph.D., vice president, clinical research for neuroscience and clinical pharmacology, Cephalon, Inc.
- Greg Bosch, CEO, PuriCore, Inc.
- Mark Bosland, managing partner, Rockport Venture Partners
- Mary Del Brady, president & CEO, RedPath Integrated Pathology, Inc.
- Todd Brady, M.D., Ph.D, principal, Domain Associates, LLC
- Keith Brownlie, partner, Ernst & Young
- Christopher Cashman, president & CEO, Protez Pharmaceuticals Inc.
- Andrew Chang, Ph.D., executive director, PharmaNet Consulting
- Richard Collier, executive vice president and general counsel, Elan Corporation, plc
- Sandra Cottrell, therapeutic area head, regulatory affairs, Novo Nordisk, Inc.
- Kathleen Coviello, director, technology & life sciences, New Jersey Economic Development Authority
- James Datin, executive vice president & managing director, life sciences group, Safeguard Scientifics, Inc.
- Sandra Dennis, deputy general counsel for health care regulatory affairs, Biotechnology Industry Organization (BIO)
- Kenneth Dow, assistant patent counsel, Johnson & Johnson
- Ron Epperson, director and national leader of the Intellectual Property Solutions Practice, Grant Thornton LLP
- Art Finnel, CFO, Phytomedics
- Richard Fitzgerald, vice president, finance and administration, Nucleonics, Inc.
- James Foley, Ph.D., CEO, SMART Biosciences
- John Fraher, chief commercial officer, Eurand, president, Eurand, Incorporated
- Matthew Gantz, CEO, Acureon Pharmaceuticals
- Andrew Gilbert, partner, Morgan, Lewis & Bockius LLP
- John Gill, president & CEO, TetraLogic Pharmaceuticals
- Daniel Greenleaf, president & CEO, VioQuest Pharmaceuticals, Inc.
- James Greenwood, president & CEO, Biotechnology Industry Organization (BIO)
- James Grigsby, president & principal owner, Grigsby & Smith
- Taren Grom, co-founder/editor-in-chief, PharmaVOICE
- Robert Grupp, vice president employee communications and corporate culture, Cephalon, Inc.
- Norman Hardman, Ph.D., serial entrepreneur
- Scott Hensley, news editor, The Wall Street Journal
- Gerri Henwood, president, Malvern Consulting Group, Inc.
- Matthew Herper, associate editor, Forbes
- Thomas Hess, vice president & CFO, Adolor Corporation
- Jane Hollingsworth, CEO, NuPathe Inc.
- Scott Horvitz, CFO, Redpoint Bio Corporation
- Robert Hrubiec, Ph.D., vice president, intellectual property, Cephalon, Inc.
- Nan Hutchinson, president, Hutchinson & Associates
- Andrew Janoff, Ph.D., chairman & CEO, Celator Pharmaceuticals
- Allan Jarvis, vice president, corporate development, sanofi pasteur
- Jason Jin, Ph.D., president & CEO, MaxyBio Corporation
- Elaine Jones, Ph.D., general partner, EuclidSR Partners
- Vishy Kanda, engagement manager, McKinsey & Company
- Perry Karsen, senior vice president, business development, Celgene Corporation
- Russel Kaufman, M.D., president & CEO, The Wistar Institute
- Jonathan Kellerman, partner, PricewaterhouseCoopers LLP
- Jeffrey Kelly, vice president of intellectual property, Kensey Nash Corporation
- David King, consultant to biotechnology ventures
- Anthony Koblish, president & CEO, Orthovita, Inc.
- Thomas Koncsics, CPA, partner, KPMG LLP
- Peter Lassota, Ph.D., divisional vice president, imaging & oncology, Caliper Life Sciences
- Mark Leahey, Esq., executive director, Medical Device Manufacturers Association (MDMA)
- Brian Lenz, CFO, VioQuest Pharmaceuticals, Inc.
- Reid Leonard, Ph.D., executive director, licensing & external research, Merck & Co., Inc.
- Doug Long, vice president of industry relations, IMS Health
- Annarie Lyles, Ph.D., senior vice president, head of business development, Genmab, Inc.
- Sandy Macrae, Ph.D., vice president of scientific licensing, cardiovascular, urogenital, metabolic, and neurosciences, GlaxoSmithKline plc
- John Maki, president & CEO, Vicus Therapeutics
- Shawn Marcell, CEO, SensiGen, LLC
- James Marino, partner, Dechert LLP
- Frank McCaney, president & CEO, Nitric BioTherapeutics
- Steve McGill, associate director, government affairs, Novo Nordisk, Inc.
- Tina Williams McKeon, principal, Fish & Richardson P.C.
- Christopher Miller, partner, Pepper Hamilton LLP
- Martina Molsbergen, vice president of business development, BioWa, Inc.
- Jeffrey Nicholas, partner, Fox Rothschild LLP
- Steven Nichtberger, M.D., president & CEO, Tengion, Inc.
- Gerard Norton, Ph.D., partner, Fox Rothschild LLP
- Shawn O'Brien, president & CEO, Solstice Neurosciences, Inc.
- James Pachence, Ph.D., president & CEO, Virium Pharmaceuticals
- Peter Paradiso, Ph.D., vice president of new business and scientific affairs, Wyeth Vaccines
- Ray Parker, Ph.D., associate vice president & head of internal medicine, U.S. Patent Department Operations, sanofi-aventis
- Bruce Peacock, venture partner, SV Life Sciences, LLC
- Kristine Peterson, company group chair, biotechnology, immunology & oncology, Johnson & Johnson
- Steven Projan, Ph.D., vice president, biological technologies, Wyeth Research
- Robert Radie, executive vice president, chief business officer, Prestwick Pharmaceuticals
- Martin Reeves, vice president strategic planning, Cephalon, Inc.
- Joseph Reiser, Ph.D., president & CEO, Locus Pharmaceuticals, Inc.
- Douglas Rogers, Jr., director northeast region, CBIZ Valuation Group, LLC
- Marc Rose, CPA, vice president, finance & CFO, Protalex, Inc.
- Avijit Roy, Ph.D., director of business development, Immunicon Corporation
- Robert Ryall, director of external R&D, sanofi pasteur
- Terrence Ryan, Ph.D., senior director, systems biology, Wyeth Research
- F. Raymond Salemme, Ph.D., CEO, Redpoint Bio Corporation
- Zev Scherl, general partner, NewSpring Capital
- Barbara Schilberg, managing director and CEO, BioAdvance
- J. Howison Schroeder, president & CEO, Neuro Kinetics, Inc.
- Alan Shaw, Ph.D., president & CEO, VaxInnate, Inc.
- David Schram, senior intellectual property counsel, Medarex, Inc.
- Daniel Skovronsky, M.D., Ph.D., president & CEO, Avid Radiopharmaceuticals, Inc.
- Martin Soeters, president, Novo Nordisk, Inc.
- Gregory Stock, Ph.D., president, Signum Biosciences
- Billy Tauzin, president & CEO, Pharmaceutical Research and Manufacturers of America (PhRMA)
- Kevin Taylor, vice president, business development, Adolor Corporation
- James Tobin, Ph.D., senior director, cardiovascular and metabolic diseases, Wyeth Research
- Paul Touhey, president & COO, Fujirebio Diagnostics, Inc.
- Steven Tullman, president & CEO, Ception Therapeutics, Inc.
- Laurie Tzodikov, technology licensing associate, Princeton University
- David U'Prichard, Ph.D., venture partner, Red Abbey Venture Partners
- Caroline West, senior vice president; chief compliance and risk officer, Shire Pharmaceuticals Group
- Dennis Willson, president & CEO, Cytokine PharmaSciences, Inc.
- Paul Woitach, managing partner, Pharmaceutical Advisors LLC
- Henry Wolfe, Ph.D., CSO, Genaera Corporation
- Chris Yochim, associate director, external relations strategic planning business development, AstraZeneca Pharmaceuticals, LP
|
